Hepatology

Zoi Papalamprakopoulou, MD, explains telehealth’s potential to aid HCV treatment in high-risk populations and how patients perceive this care modality.

Zhang describes how a novel multidisciplinary care clinic has helped reduce relapse after transplant in patients with alcohol-associated liver disease.

New phase 2b data suggest a combination of VTP-300 and low-dose nivolumab can stimulate immune response and induce HBV functional cure.

Findings from a 2.5-year interim analysis from the ongoing phase 3 ASSURE study highlight seladelpar’s sustained efficacy and long-term safety for PBC.

In areas where HBV immune globulin is not available, maternal TDF therapy at week 16 and infant HBV vaccination can prevent mother-to-child transmission.

A study presented at NASPGHAN 2024 reveals rising incidence rates and improved survival outcomes of Biliary Atresia in the US.

The risk score uses routine clinical data to assess hepatocellular carcinoma risk in patients without viral hepatitis or hepatic decompensation.

The CRL is consistent with the outcome of a September Gastrointestinal Drugs Advisory Committee meeting.

Alkhouri explains the first real-world data on the use of resmetirom (Rezdiffra) in patients with MASH and how they compare to clinical trial findings.

Phase 1b data support proof-of-principle for EBX-102 across microbiome and clinical assessments as well as inflammatory biomarkers for cirrhosis.

Research presented at NASPGHAN 2024 found most children with chronic hepatitis C had neurodevelopmental disorders, highlighting the need for proactive care.

PEDFIC data at NASPGHAN 2024 show mild, transient diarrhea events with odevixibat for cholestatic pruritus in PFIC, resolving in most cases.

Meta-analysis of 30 studies highlights serum markers as prognostic tools for liver survival post-portoenterostomy in biliary atresia.

New data from the UNOS database presented at NASPGHAN 2024 details characteristics and outcomes of pediatric liver transplant patients receiving machine perfused organs.

Noureddin explains the efficacy of resmetirom doses and how they vary based on patients’ body weight and BMI, supporting current prescribing practices.

MASEF score seemed to be sensitive and effective in detecting at-risk MASH in 2 abstracts presented at the ACG 2024 Meeting.

Investigators highlighted the long-term cost-effectiveness of routine HCV screening as well as linkage-to-care for high-risk patients in emergency departments.

Chronic hepatitis B patients with HBsAg <100 IU/mL and HBcrAg <3 log U/mL at nucleot(s)ide analog therapy had lower relapse risk.

Phase 3, 3b, and 4 clinical trials will provide long-term insight into the use of elafibranor in different PBC patient populations and real-world settings.

Direct-acting antiviral agents have enabled more availability for organ transplant.

This hepatology month in review spotlights hepatic pipeline news, research on treating and eliminating viral hepatitis, and HCPLive’s coverage of ACG 2024.

Alcohol relapses were detected more frequently after the introduction of phosphatidylethanol in orthotopic liver transplant recipients.

Despite the number of individuals with MASLD-related HCC without cirrhosis who report a low FIB-4, current care pathways may not identify such patients for additional assessments.

Normothermic machine perfusion in liver transplants improves preservation, reduces early complications, and shows promise in complex cases.

Headline results from part 1 of the phase 3 ESSENCE trial highlight semaglutide 2.4 mg’s benefits for fibrosis and steatohepatitis in patients with MASH.

Open-label, interim data from ASSURE shows positive effect and tolerability with once-daily seladelpar in patients with primary biliary cholangitis and compensated cirrhosis.

A qualitative / quantitative study shows significant gaps in PBC diagnosis confidence and skill between care providers.

Only about 2% of eligible patients with ALD have received a pharmacotherapy for alcohol use disorder—and the prescription takes more than a year to receive.

Mayo explains elafibranor’s benefit for patients with advanced-stage primary biliary cholangitis based on findings from a new ELATIVE analysis.

Data from ACG 2024 show only 1 in 12 patients eligible for second-line PBC therapy are actually doing receiving it—and it may take up to a year to initiate.